Table 3.
Univariate and multivariate analyses of progression-free survival.
| Univariate analysis | Multivariate analysis | |||
|---|---|---|---|---|
| HR (95% CI) | P-value | HR (95% CI) | P-value | |
| Age, years | ||||
| < 55 | 1.40 (0.88-2.24) | 0.156 | 1.46 (0.80-2.67) | 0.212 |
| ≥ 55 | 1 [Reference] | NA | 1 [Reference] | NA |
| Gender | ||||
| Male | 1 [Reference] | NA | 1 [Reference] | NA |
| Female | 1.49 (0.91-2.45) | 0.115 | 1.44 (0.74-2.79) | 0.282 |
| ECOG PS | ||||
| 0 | 1 [Reference] | NA | 1 [Reference] | NA |
| 1 | 1.09 (0.67-1.78) | 0.721 | 0.99 (0.56-1.75) | 0.979 |
| 2-3 | 3.35 (1.14-9.80) | 0.027 | 1.49 (0.39-5.79) | 0.561 |
| Smoking status | ||||
| Never smoker | 1.16 (0.72-1.86) | 0.545 | 1 [Reference] | NA |
| Current or former smoker | 1 [Reference] | NA | 1.18 (0.60-2.33) | 0.637 |
| Histology | ||||
| Squamous cell carcinoma | 1 [Reference] | NA | 1 [Reference] | NA |
| Nonsquamous cell carcinoma | 1.14 (0.70-1.87) | 0.590 | 1.11 (0.55-2.24) | 0.780 |
| No. of prior treatment lines | ||||
| 0-1 | 1 [Reference] | NA | 1 [Reference] | NA |
| ≥2 | 2.98 (1.76-5.02) | <0.001 | 3.36 (1.58-7.15) | 0.002 |
| No. of metastatic sites | ||||
| 1-2 | 1 [Reference] | NA | 1 [Reference] | NA |
| ≥3 | 2.52 (1.55-4.10) | <0.001 | 1.97 (1.00-3.88) | 0.051 |
| Prior radiotherapy | ||||
| Yes | 1.10 (0.64-1.90) | 0.736 | 1 [Reference] | NA |
| No | 1 [Reference] | NA | 1.92 (0.96-3.83) | 0.066 |
| EGFR mutation status | ||||
| Negative | 1 [Reference] | NA | 1 [Reference] | NA |
| Positive | 2.00 (0.98-4.06) | 0.056 | 1.00 (0.39-2.61) | 0.917 |
| Not available | 1.41 (0.80-2.49) | 0.233 | 2.80 (0.73-10.77) | 0.135 |
| ALK translocation | ||||
| Negative | 1 [Reference] | NA | 1 [Reference] | NA |
| Positive | 4.69 (1.61-13.70) | 0.005 | 2.43 (0.67-8.82) | 0.177 |
| Not available | 1.24 (0.74-2.08) | 0.424 | 0.59 (0.18-1.86) | 0.365 |
| SLD0, mm | ||||
| ≤ 130 | 1 [Reference] | NA | 1 [Reference] | NA |
| > 130 | 5.79 (2.64-12.73) | <0.001 | 10.70 (4.20-27.23) | <0.001 |
| TGR0, %/m | ||||
| ≤ 25.3 | 1 [Reference] | NA | 1 [Reference] | NA |
| > 25.3 | 1.97 (1.21-3.21) | 0.006 | 1.97 (1.08-3.60) | 0.026 |
HR, hazard ratio; CI, confidence interval; NA, not applicable; ECOG PS, Eastern Cooperative Oncology Group performance status; EGFR, epidermal growth factor receptor; ALK, anaplastic lymphoma kinase; SLD0, sum of the longest diameters of the target lesions at baseline; TGR0, pre-treatment tumor growth rate.